In contrast to hereditary angioedema (HAE) due to C1-inhibitor deficiency, the detection of pathogenic variants in genes linked to HAE with normal C1 inhibitor levels (HAE-nC1INH) is required for the diagnosis of the corresponding types of the disease….
Neoantigens, derived from tumor-specific mutations, are promising targets of cancer immunotherapy by eliciting tumor-specific T-cell responses while sparing normal cells. Accurate neoantigen prediction relies on immunogenomics and immunopeptidomics. Im…
Gasdermin E (GSDME), a key executor of pyroptosis, exerts a unique dual role in tumorigenesis, acting as both a tumor suppressor and a tumor-promoting factor. Due to promoter hypermethylation, GSDME is epigenetically silenced in most solid tumors, incl…
Liver cancer is a major global health burden, with hepatocellular carcinoma (HCC) being the most common type. Liver cancer tumor-initiating cells (TICs) are responsible for recurrence, metastasis, and therapeutic resistance, thereby presenting formidab…
T cell development and function depend on precise remodeling of the actin cytoskeleton, which regulates migration, cell division, immunological synapse formation, and signal transduction. Regulators of actin include nucleators (Arp2/3, Formins) and bin…
Cancers, with its rising incidence strongly linked to human papillomavirus (HPV) infection, particularly HPV16. HPV-induced OPSCC (HPV-OPSCC) exhibits distinct biological behaviors, including a high propensity for early lymphatic metastasis, occurring …
Non-small cell lung cancer (NSCLC) immunotherapy has been revolutionized by immune checkpoint inhibitors (ICIs), yet response heterogeneity persists due to dynamic tumor-immune interactions. This review summarizes recent studies in understanding tumor-…
B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy, accounting for 20-25% of all new cancer diagnoses in North American children each year. The leukemia arises, most commonly after a latency of 3–5 years, from a preleuk…
Cancer immunotherapy has emerged as a powerful strategy for clinical treatment of malignant cancers. Despite the advances, cancer immunotherapy has met several challenges such as the limited efficacy to small subsets of patients, and serious autoimmune…
Platinum-based first-line chemotherapy for small lung cancers has been a mainstream therapy for the past several decades. However, its efficacy has been suboptimal, and the research is now focused on improving the treatment and prognosis of competitive…
